In an interview with CNBC-TV18s Sumaira Abidi, Kumar said the FDAs decision to allow US Teva to launch a cheaper copy of AstraZenecas Nexium (esomeprazole) may result in a 3-5 percent earnings upgrade for Cipla as the Indian company is a formulations supplier to Teva and has a 30 percent p